Fig. 1: PLK1 knockdown by siRNA induces PD-L1 expression.
From: Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
a PLK1 and PD-L1 mRNA expression in A549 (human NSCLC) at 48 h post treatment with PLK1 siRNA (siPLK1) or scrambled siRNA (siSCR) normalized to HPRT housekeeping gene. Dharmafect 1 transfection agent was used. Data presented as mean ± SD from 3 independent samples; ****P < 0.0001 (Unpaired t-test; two-tailed). PD-L1 surface expression of (b) A549 and (c) LLC-JSP at 72 h post treatments assessed by flow cytometry. Data presented as histogram of individual events (cells); ****P < 0.0001 for A549 siPLK1 vs. untreat; ****P < 0.0001 for LLC-JSP siPLK1 vs. untreat (Unpaired t-test; two-tailed). Source data are provided as a Source Data file.
